Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial
Journal article published in 2019 by
K. W. Mahaffey,
M. J. Jardine,
S. Bompoint,
C. P. Cannon,
B. Neal,
H. J. L. Heerspink,
D. M. Charytan,
R. Edwards,
R. Agarwal,
G. Bakris,
S. Bull,
G. Capuano,
D. De Zeeuw,
T. Greene 
,
A. Levin
and other authors.
,
A. Levin
and other authors.
